Daiichi Sankyo’s Deal With Ranbaxy Hits A Snag
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - There is trouble for Japanese drug maker Daiichi Sankyo's takeover proposal of India's largest pharmaceutical company Ranbaxy as India's stock market regulator, the Securities and Exchange Board of India, has rejected a plea from Ranbaxy promoters to execute the 34.8 percent stake sale to Daiichi Sankyo through live-market transactions
You may also be interested in...
2008 Deals Of The Year
Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY
2008 Deals Of The Year
Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY
Ranbaxy Officially Becomes A Daiichi Subsidiary As Management Turns To Business Synergies
MUMBAI - Daiichi Sankyo has acquired 52.5 percent of Ranbaxy's equity share capital for $736 million. Ranbaxy announced that the committee of the board of directors of Ranbaxy approved Oct. 20 the allotment of equity shares and warrants on a preferential basis to Daiichi Sankyo. With this Ranbaxy has officially become a subsidiary of Daiichi Sankyo